Re: “High Thyroid Cancer Mortality Rate in Japan: A Result of Nonaggressive Treatment Strategy,or Just an Aging Population?” By Magner ( Thyroid 2018;28:818–819)
Restricted accessLetterFirst published online June, 2018
Re: “High Thyroid Cancer Mortality Rate in Japan: A Result of Nonaggressive Treatment Strategy,or Just an Aging Population?” By Magner ( Thyroid 2018;28:818–819)
MagnerJ. 2018. High thyroid cancer mortality rate in Japan: a result of nonaggressive treatment strategy, or just an aging population?. Thyroid, 28:818–819.
2.
La VecchiaC, MalvezziM, BosettiC, GaravelloW, BertuccioP, LeviF, NegriE. 2015. Thyroid cancer mortality and incidence: a global overview. Int J Cancer, 136:2187–2195.
3.
World life expectancy—WHO 2014 data by country. Available at: www.worldlifeexpectancy.com/ (accessed March20, 2018).
4.
TakamiH, ItoY, OkamotoT, YoshidaA. 2011. Therapeutic strategy for differentiated thyroid carcinoma in Japan based on a newly established guideline managed by Japanese Society of Thyroid Surgeons and Japanese Association of Endocrine Surgeons. World J Surg, 35:111–121.
5.
HaugenBR, AlexanderEK, BibleKC, DohertyGM, MandelSJ, NikiforovYE, PaciniF, RandolphGW, SawkaAM, SchlumbergerM, SchuffKG, ShermanSI, SosaJA, StewardDL, TuttleRM, WartofskyL. 2016. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid, 26:1–133.
6.
ItoY, MiyauchiA, KiharaM, FukushimaM, HigashiyamaT, MiyaA. 2018. Overall survival of papillary thyroid carcinoma patients: a single-institution long-term follow-up of 5897 patients. World J Surg, 42:615–622.
7.
Cancer Fast Stats—The National Cancer Institute. Available at: http://seer.cancer.gov/faststats/ (accessed March20, 2018).
8.
EbinaA, SugitaniI, YoshihideF, YamadaK. 2014. Risk-adapted managment of papillary thyroid carcinoma according to our own risk group classification system: is thyroid lobectomy the treatment of choice for low risk patients?. Sugery, 156:1579–1589.
9.
SugitaniI, KasaiN, FujimotoY, YanagisawaA. 2004. A novel classification system for patients with PTC: addition of the new variables of large (3 cm or greater) nodal metastases and reclassification during the follow-up period. Surgery, 135:139–148.
10.
HayID, ThompsonGB, GrantCS, BergstralhEJ, DvorakCE, GormanCA, MaurerMS, McIverB, MullanBP, ObergAL, PowellCC, van HeerdenJA, GoellnerJR. 2002. Papillary thyroid carcinoma managed at the Mayo Clinic during six decades (1940–1999): temporal trends in initial therapy and long-term outcome in 2444 consecutively treated patients. World J Surg, 26:879–885.
11.
MatsuzuK, SuginoK, MasudoK, NagahamaM, KitagawaW, ShibuyaH, OhkuwaK, UrunoT, SuzukiA, MagoshiS, AkaishiJ, MasakiC, KawanoM, SuganumaN, RinoY, MasudaM, KameyamaK, TakamiH, ItoK. 2014. Thyroid lobectomy for papillary thyroid cancer: long-term follow-up study of 1,088 cases. World J Surg, 38:68–79.
12.
SugitaniI, FujimotoY. 2010. Does postoperative thyrotropin suppression therapy truly decrease recurrence in papillary thyroid carcinoma? A randomized controlled trial. J Clin Endocrinol Metab, 95:4576–4583.
